DiaMedica Therapeutics Inc logo

DiaMedica Therapeutics Inc

NEW
NAS:DMAC (USA)  
$ 4.95 +0.020 (+0.41%) 07:08 PM EST
At Loss
P/B:
5.21
Market Cap:
$ 212.14M
Enterprise V:
$ 167.47M
Volume:
50.06K
Avg Vol (2M):
80.59K
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
50.06K
At Loss
Avg Vol (2M):
80.59K

Business Description

DiaMedica Therapeutics Inc logo
DiaMedica Therapeutics Inc
NAICS : 325412 SIC : 3741
ISIN : CA25253X1087
Description
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Name Current Vs Industry Vs History
Cash-To-Debt 129.84
Equity-to-Asset 0.88
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.28
Quick Ratio 8.28
Cash Ratio 8.19

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -17.4
Shareholder Yield % -5.3
Name Current Vs Industry Vs History
ROE % -51.03
ROA % -47.17
ROIC % -1176.82
3-Year ROIIC % -578.71
ROC (Joel Greenblatt) % -5805.27
ROCE % -55.38

Financials (Next Earnings Date:2025-05-09 Est.)

DMAC's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:DMAC

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

DiaMedica Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.6
Beta 0.79
3-Year Sharpe Ratio 0.68
3-Year Sortino Ratio 1.46
Volatility % 39.07
14-Day RSI 34
14-Day ATR ($) 0.347759
20-Day SMA ($) 5.749
12-1 Month Momentum % 127.27
52-Week Range ($) 2.14 - 6.8184
Shares Outstanding (Mil) 42.86

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

DiaMedica Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

DiaMedica Therapeutics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

DiaMedica Therapeutics Inc Frequently Asked Questions

What is DiaMedica Therapeutics Inc(DMAC)'s stock price today?
The current price of DMAC is $4.95. The 52 week high of DMAC is $6.82 and 52 week low is $2.14.
When is next earnings date of DiaMedica Therapeutics Inc(DMAC)?
The next earnings date of DiaMedica Therapeutics Inc(DMAC) is 2025-05-09 Est..
Does DiaMedica Therapeutics Inc(DMAC) pay dividends? If so, how much?
DiaMedica Therapeutics Inc(DMAC) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1